Rallybio (RLYB) Return on Sales (2024 - 2026)

Rallybio (RLYB) posted Return on Sales of 0.39% for Q1 2026, down 48.13% sequentially from 0.26% in Q4 2025, and up 3.0% YoY from 0.38% in Q1 2025.

Rallybio (RLYB) Return on Sales (2024 - 2026) Analysis & Trends

Rallybio has reported Return on Sales for 3 years, with the latest figure at 0.39% in Q1 2026.

Quarterly Return on Sales rose 3.0% year-over-year to 0.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.09% (up 46.0% YoY) and the FY2025 annual result came in at 0.09%, up 78.0% from the prior year.
Return on Sales slipped to 0.39% in Q1 2026 per RLYB's latest filing, from 0.26% in the prior quarter.
Over five years, Return on Sales peaked at 0.76% in Q3 2025 and troughed at 2.79% in Q4 2024.
A 3-year average of 0.56% and a median of 0.4% in 2025 frame the typical range for Return on Sales.
The sharpest annual moves came in 2025 and 2026: Return on Sales jumped 253 bps in 2025, then grew 3 bps in 2026.
Over 3 years, Return on Sales stood at 2.79% in 2024, then surged by 91 bps to 0.26% in 2025, then sank by 48 bps to 0.39% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.39%, 0.26%, and 0.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Rallybio	94.61 Mn	94.61 Mn	-	0.71%

Download Data